Join the Oncology Voice Network. Join for Free
Stop Counting Interactions. Start Measuring Impact.

Stop Counting Interactions. Start Measuring Impact.


Share This Article


Summary

The industry tracks reach, frequency, and engagement. But none of those metrics tell you whether you actually changed a clinical decision.

Stop Counting Interactions. Start Measuring Impact.

One Idea Worth Acting On.

An MSL logs their fifteenth KOL meeting of the week.

The CRM dashboard turns green.

Leadership celebrates a hit metric.

The actual feedback from the visit: "The physician likes the study."

That is not a strategic insight. That is a comment. And under most current systems, it is counted, celebrated, and reported upward as evidence of impact.

What's Actually Happening

Field Medical exists to do one thing: generate strategic intelligence from the external healthcare ecosystem and route it to the internal functions that need it. MSLs are uniquely positioned to hear what practicing oncologists are thinking about current treatments, emerging data, unmet patient needs, and competitive positioning — intelligence that cannot be found in any database.

But when the measure of success is the number of interactions, the system trains MSLs to optimize for volume rather than depth.

As Dr. Robin Winter-Sperry, pharmaceutical industry strategist and contributor to Voices of Oncology, explains: an MSL reporting back that "the physician likes the study" is not a strategic insight. Yet under many current measurement systems, that observation is captured, entered into the CRM, counted toward the weekly target, and reported upward as meaningful field intelligence.

The result is a dangerous illusion of productivity. Activity metrics are green. Strategic value is invisible.

Why This Matters

The questions that matter most in oncology drug development — which patient subpopulations are underserved, where the real-world prescribing patterns diverge from the label, what objections physicians are raising that the company has not heard — are answered in MSL field conversations. Not in CRM dashboards.

When MSLs are incentivized to maximize call frequency, they have less time to cultivate the relationships that produce genuine insight. Brief, transactional interactions replace the deeper scientific exchanges that generate the intelligence the organization actually needs.

The insight that would have changed the publication strategy, the safety communication approach, or the label expansion decision never arrived — because the system that was supposed to route it was optimized for something else entirely.

Where It Breaks in the Real World

A Medical Affairs function invests in a new CRM platform to improve insight tracking. Six months later, the volume of submitted insights has tripled. Leadership declares success.

But when the submissions are analyzed, the majority are brief, non-actionable observations — physician comments about competitive products, general satisfaction ratings, note-taking from presentations the MSL attended. The insights that would require a change in strategy, a new publication, or a response from Clinical Development are buried or absent entirely.

The platform measured submission volume. It had no way to measure whether the submissions changed any decision.

What Needs to Change

Field Medical metrics need to measure what they are actually trying to produce: strategic insights that reach the internal functions whose decisions they should inform, and evidence that those decisions changed as a result.

That requires two things: a quality standard for what constitutes a meaningful field insight, and a routing mechanism that ensures qualified insights reach the strategy, publication, and clinical development teams — not just the CRM inbox.

The organizations building that infrastructure are discovering that fewer, better insights from well-cultivated relationships are worth more than thousands of brief interactions that never move a decision.

The Bottom Line

Activity is not impact. Interactions are not intelligence.

Until Field Medical is measured on what its insights actually change — not how many were submitted — the function will keep producing the metric it is asked for and delivering far less than it is capable of.

Add Your Voice — Where are you seeing this? What's working — and what's not?

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN